Meanwhile, regulation of ERK1/2 activity is associated with cardiovascular disease, and inhibitors decreased ERK1/2 activity and increased aortic elastin content, suggesting the feasibility of ERK1/2 inhibitors in the treatment of AS with reduced arterial elastin content (Zeng et al., 2021). The gene discussed is MAPK3; the disease is cardiovascular disorder.